Browse by Industry
Filter News
Found 144,066 articles
-
BIIB080 successfully reduced tau pathology in patients with early-stage disease across all six brain regions analyzed.
-
The RSV race has lost one high-profile contender as Janssen announced it is discontinuing the Phase III EVERGREEN trial studying its RSV vaccine candidate.
-
In an earnings call Wednesday, bluebird bio revealed it is unlikely to meet its first-quarter goal to submit a Biologics License Application for sickle cell disease (SCD) gene therapy lovo-cel.
-
GSK will help commercialize Brexafemme (ibrexafungerp), currently approved to treat vaginal yeast infections and vulvovaginal candidiasis (VVC).
-
A federal court sided in favor of Vanda Pharmaceuticals in its Freedom of Information Act case against the FDA regarding the CRL for its sleep drug label expansion.
-
Top Biotech Licensing Deals of Q1 2023
3/30/2023
There have already been several big biotech licensing deals in Q1. See inside for some of this quarter's biggest licensing deals — from the surprising and pivotal to the lucrative and consequential. -
Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility
3/30/2023
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, and the Government of the Republic of Kenya have finalized an agreement to establish an mRNA manufacturing facility in the Republic of Kenya.
-
BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity
3/30/2023
BeiGene, a global biotechnology company, announced the appointment of Julius Pryor III as its first Global Head of Diversity and Health Equity, effective immediately.
-
ThirtyFiveBio Emerges From Stealth with Presentation of First Data from GPR35 Antagonist Program at American Association for Cancer Research (AACR) Annual Meeting 2023
3/30/2023
ThirtyFiveBio Limited emerged from stealth and announced that it will present the first data from its GPR35 antagonist program at the upcoming American Association for Cancer Research Annual Meeting 2023.
-
Abcam, plc Publication of 2022 Annual Report and Accounts and Notice of Annual General Meeting
3/30/2023
Abcam plc announces that, following release on 20 March 2023 of its final results for the year ended 31 December 2022 on Form 20-F with the Securities and Exchange Commission, the Abcam plc Annual Report and Accounts 2022 have been published and are available on the Abcam plc website
-
Tonix Pharmaceuticals Presents Positive Efficacy and Safety Data from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 5th International Congress on Controversies in Fibromyalgia
3/30/2023
Tonix Pharmaceuticals Holding Corp. announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present an oral presentation and poster at the 5th International Congress on Controversies in Fibromyalgia being held March 30-31, 2023 at the Austria Trend Hotel Savoyen Vienna in Vienna, Austria.
-
Ad Astra Diagnostics files 510(k) for QScout™ hematology analyzer
3/30/2023
Ad Astra Diagnostics, developer of rapid diagnostic systems, announced that it has submitted a 510 application to the U.S. Food and Drug Administration for its QScout RLD rapid-result hematology system intended to report white blood cell count, neutrophil-to-lymphocyte ratio, and counts of six white blood cell types in fingerstick or venous blood.
-
EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases
3/30/2023
EIP Pharma Inc. and Diffusion Pharmaceuticals Inc., announced that the companies have entered into a definitive merger agreement for an all-stock transaction forming a publicly traded, combined company that will focus on the advancement of EIP Pharma’s pioneering pipeline of oral stress kinase inhibitors, including its lead drug candidate neflamapimod, which is currently being developed for the treatment of dementia with Lewy bodies.
-
Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors
3/30/2023
Alaunos Therapeutics, Inc., a leading T-cell receptor cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, announced the appointment of Robert J. Hofmeister, PhD, MS, Chief Scientific Officer of a stealth early stage biotechnology company, to the Company’s Board of Directors, effective immediately.
-
Trevena Reports Fourth Quarter 2022 Results and Provides Business Update
3/30/2023
Trevena, Inc. reported its financial results for the fourth quarter ended December 31, 2022 and provided an overview of its recent operational highlights.
-
Microbix Announces Annual and Special Meeting Voting Results - March 30, 2023
3/30/2023
Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces the voting results from the Annual and Special Meeting of Shareholders of the Company which was held on March 29, 2023.
-
CorMedix Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3/30/2023
CorMedix Inc. announced financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on recent business developments.
-
XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio
3/30/2023
XOMA Corporation, announced it has acquired the commercial payment and a portion of the milestone rights to IXINITY® [coagulation factor IX ], which is marketed by Medexus Pharmaceuticals for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B, from Aptevo Therapeutics.
-
ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson’s Disease Dementia
3/30/2023
Anavex Life Sciences Corp. reports preliminary 48-week open-label extension Parkinson’s disease dementia ANAVEX®2-73-PDD-EP-001 Phase 2 study data which demonstrated longitudinal beneficial effects of ANAVEX®2-73 on the prespecified primary and secondary objectives, as well as planned primary and key secondary endpoints which will be utilized in a forthcoming pivotal study of ANAVEX®2-73 in Parkinson’s disease.
-
Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors
3/30/2023
Zevra Therapeutics announced that it has appointed Wendy L. Dixon, Ph.D., to the Company’s Board of Directors, effective immediately following the conclusion of the 2023 Annual Meeting of Stockholders, to fill the vacancy resulting from Dr. Travis Mickle’s resignation from the Board effective as of the day of the 2023 Annual Meeting to be held on April 25, 2023.